Mifamurtide (Adjuvant for High-Grade Osteosarcoma, non-US approval)
Treatment for Malignant neoplasm of bone and articular cartilage
Typical Dosage: 2 mg liposomal muramyl tripeptide intravenously
Effectiveness
55%
Safety Score
60%
Clinical Trials
15
Participants
2K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
60
DangerousModerateSafe
Treatment Details
Dosage Range
2 mg liposomal muramyl tripeptide intravenously
Time to Effect
Months (during treatment course)
Treatment Duration
48 weeks (twice weekly for 24 weeks, then weekly for 24 weeks)
Evidence Quality
MODERATEConfidence Score
65%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$120,000
Monitoring:$1,000
Side Effect Mgmt:$2,000
Total Annual:$123,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
POORICER
$250,000/QALY
QALYs Gained
0.2
Comparison vs Standard Chemotherapy Alone
Cost Difference
+$123,000/year
More expensive
QALY Difference
+0.20 QALYs
Better outcomes
Dominance
No dominance
Mifamurtide (Adjuvant for High-Grade Osteosarcoma, non-US approval) Outcomes
for Malignant neoplasm of bone and articular cartilage
Efficacy Outcomes
Overall Effectiveness
+55%
Common Side Effects
Fever/Chills
+50%
Fatigue
+40%
Headache
+25%
Nausea/Vomiting
+25%
Hypotension
+7%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov